Lv3
340 积分 2025-12-17 加入
Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis
2个月前
已完结
Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma
3个月前
已完结
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population
3个月前
已完结
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study
3个月前
已完结
TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study
3个月前
已完结
Efficacy and liver function preservation with donafenib combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: An ALBI grade analysis
3个月前
已完结
Atezolizumaba plus bevacizumab is Associated with Favorable Overall Survival Over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma
3个月前
已完结
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma
3个月前
已完结
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database
3个月前
已完结
Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study
3个月前
已完结
皖公网安备34019202002308
